echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Betta Pharmaceuticals PD-1 batilimumab was approved for clinical use

    Betta Pharmaceuticals PD-1 batilimumab was approved for clinical use

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the CDE official website shows that the PD-1 monoclonal antibody Balstilimab (Balstilimab), a collaboration between Betta Pharmaceuticals and Agenus, has been approved for clinical use in advanced cervical cancer
    .

    Bartilimumab is one of the two monoclonal antibody products acquired by Betta Pharmaceuticals from Agenus with a US$15 million down payment + US$20 million shares.
    The other is the CTLA-4 monoclonal antibody Zalifrelimab
    .


    Through this transaction, Betta has obtained the exclusive development and commercialization rights of these two products in China (including Hong Kong, Macau and Taiwan) for single use or in combination with other drugs to treat all indications except intravesical administration


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.